Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)

Froment, Pascal; Touraine, Philippe

doi:https://doi.org/10.1155/PPAR/2006/73986

PPAR Research

On this page

Abstract References Copyright Related Articles

Review Article | Open Access

Volume 2006 | Article ID 073986 | https://doi.org/10.1155/PPAR/2006/73986

Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)

Pascal Froment¹and Philippe Touraine²

Received15 Jul 2006

Revised13 Oct 2006

Accepted17 Oct 2006

Published06 Nov 2006

Abstract

Polycystic ovary syndrome (PCOS) is the most frequent cause of female infertility. The treatment of PCOS patients with insulin sensitizers, such as metformin or thiazolidinediones, increases the ovulation rate and the number of successful pregnancies. The positive action of the insulin-sensitizing treatments could be explained by a decrease in the peripheral insulin resistance but also by a direct action at the ovarian level. We report in this review different hypotheses of thiazolidinediones actions to improve PCOS (steroid secretion by ovarian cells ; insulin sensitivity in muscle and adipocyte and fat redistribution).

References

A Dunaif, “Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis,” Endocrine Reviews, vol. 18, no. 6, pp. 774–800, 1997.
View at: Publisher Site | Google Scholar
C Deneux and F Kuttenn, “Hyperandrogenism and fertility,” Annales d'Endocrinologie, vol. 59, no. 4, pp. 311–318, 1998.
View at: Google Scholar
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004.
View at: Publisher Site | Google Scholar
A Dunaif, “Insulin action in the polycystic ovary syndrome,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 341–359, 1999.
View at: Publisher Site | Google Scholar
S SC Yen, “The polycystic ovary syndrome,” Clinical Endocrinology, vol. 12, no. 2, pp. 177–207, 1980.
View at: Google Scholar
J C Marshall and C A Eagleson, “Neuroendocrine aspects of polycystic ovary syndrome,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 295–324, 1999.
View at: Publisher Site | Google Scholar
K A Risma, C M Clay, T M Nett, T Wagner, J Yun, and J H Nilson, “Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1322–1326, 1995.
View at: Publisher Site | Google Scholar
L Poretsky, “Polycystic ovary syndrome—increased or preserved ovarian sensitivity to insulin?,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2859–2860, 2006.
View at: Publisher Site | Google Scholar
J R Wood, V L Nelson, C Ho et al., “The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis,” Journal of Biological Chemistry, vol. 278, no. 29, pp. 26380–26390, 2003.
View at: Publisher Site | Google Scholar
R B Barnes, “Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome,” Seminars in Reproductive Endocrinology, vol. 15, no. 2, pp. 159–168, 1997.
View at: Google Scholar
S Franks, C Gilling-Smith, H Watson, and D Willis, “Insulin action in the normal and polycystic ovary,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 361–378, 1999.
View at: Publisher Site | Google Scholar
C Bergh, B Carlsson, J-H Olsson, U Selleskog, and T Hillensjo, “Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin,” Fertility and Sterility, vol. 59, no. 2, pp. 323–331, 1993.
View at: Google Scholar
S K Blank, C R McCartney, and J C Marshall, “The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome,” Human Reproduction Update, vol. 12, no. 4, pp. 351–361, 2006.
View at: Publisher Site | Google Scholar
V De Leo, A La Marca, and F Petraglia, “Insulin-lowering agents in the management of polycystic ovary syndrome,” Endocrine Reviews, vol. 24, no. 5, pp. 633–667, 2003.
View at: Publisher Site | Google Scholar
M J Iuorno and J E Nestler, “Insulin-lowering drugs in polycystic ovary syndrome,” Obstetrics and Gynecology Clinics of North America, vol. 28, no. 1, pp. 153–164, 2001.
View at: Publisher Site | Google Scholar
J E Nestler, D J Jakubowicz, P Reamer, R D Gunn, and G Allan, “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome,” New England Journal of Medicine, vol. 340, no. 17, pp. 1314–1320, 1999.
View at: Publisher Site | Google Scholar
E Seli and A J Duleba, “Treatment of PCOS with metformin and other insulin-sensitizing agents,” Current Diabetes Reports, vol. 4, no. 1, pp. 69–75, 2004.
View at: Google Scholar
J M Lehmann, L B Moore, T A Smith-Oliver, W O Wilkison, T M Willson, and S A Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor $γ$ (PPAR $γ$ ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.
View at: Publisher Site | Google Scholar
B Desvergne and W Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
View at: Publisher Site | Google Scholar
H N Sørensen, E Treuter, and J A Gustafsson, “Regulation of peroxisome proliferator-activated receptors,” Vitamins and Hormones, vol. 54, pp. 121–166, 1998.
View at: Google Scholar
F Picard and J Auwerx, “PPAR $γ$ and glucose homeostasis,” Annual Review of Nutrition, vol. 22, pp. 167–197, 2002.
View at: Publisher Site | Google Scholar
J Girard, “Mechanisms of action of thiazolidinediones,” Diabetes and Metabolism, vol. 27, no. 2 pt 2, pp. 271–278, 2001.
View at: Google Scholar
M Gurnell, D B Savage, V KK Chatterjee, and S O'Rahilly, “The metabolic syndrome: peroxisome proliferator-activated receptor $γ$ and its therapeutic modulation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2412–2421, 2003.
View at: Publisher Site | Google Scholar
B Staels and J-C Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005.
View at: Google Scholar
C M Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, vol. 3, p. 41, 2005.
View at: Publisher Site | Google Scholar
P Froment, F Gizard, D Defever, B Staels, J Dupont, and P Monget, “Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition,” Journal of Endocrinology, vol. 189, no. 2, pp. 199–209, 2006.
View at: Publisher Site | Google Scholar
C M Komar, O Braissant, W Wahli, and T E Jr Curry, “Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period,” Endocrinology, vol. 142, no. 11, pp. 4831–4838, 2001.
View at: Publisher Site | Google Scholar
C M Komar and T E Jr Curry, “Inverse relationship between the expression of messenger ribonucleic acid for peroxisome proliferator-activated receptor $γ$ and P450 side chain cleavage in the rat ovary,” Biology of Reproduction, vol. 69, no. 2, pp. 549–555, 2003.
View at: Publisher Site | Google Scholar
A Abe, Y Kiriyama, M Hirano et al., “Troglitazone suppresses cell growth of KU812 cells independently of PPAR $γ$ ,” European Journal of Pharmacology, vol. 436, no. 1-2, pp. 7–13, 2002.
View at: Publisher Site | Google Scholar
N K LeBrasseur, M Kelly, T-S Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology - Endocrinology and Metabolism, vol. 291, no. 1, pp. E175–E181, 2006.
View at: Publisher Site | Google Scholar
M A Khan, J V St. Peter, and J L Xue, “A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone,” Diabetes Care, vol. 25, no. 4, pp. 708–711, 2002.
View at: Google Scholar
D L Stout and S E Fugate, “Thiazolidinediones for treatment of polycystic ovary syndrome,” Pharmacotherapy, vol. 25, no. 2, pp. 244–252, 2005.
View at: Publisher Site | Google Scholar
R Azziz, D Ehrmann, R S Legro et al., “Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1626–1632, 2001.
View at: Publisher Site | Google Scholar
I Hasegawa, H Murakawa, M Suzuki, Y Yamamoto, T Kurabayashi, and K Tanaka, “Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome,” Fertility and Sterility, vol. 71, no. 2, pp. 323–327, 1999.
View at: Publisher Site | Google Scholar
D A Ehrmann, D J Schneider, B E Sobel et al., “Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 7, pp. 2108–2116, 1997.
View at: Publisher Site | Google Scholar
A Dunaif, D Scott, D Finegood, B Quintana, and R Whitcomb, “The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3299–3306, 1996.
View at: Publisher Site | Google Scholar
D Glintborg, A P Hermann, M Andersen et al., “Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 86, no. 2, pp. 385–397, 2006.
View at: Publisher Site | Google Scholar
H M Garmes, M A Tambascia, and D E Zantut-Wittmann, “Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 21, no. 6, pp. 317–323, 2005.
View at: Publisher Site | Google Scholar
N Brettenthaler, C De Geyter, P R Huber, and U Keller, “Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3835–3840, 2004.
View at: Publisher Site | Google Scholar
D Romualdi, M Guido, M Ciampelli et al., “Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome,” Human Reproduction, vol. 18, no. 6, pp. 1210–1218, 2003.
View at: Publisher Site | Google Scholar
N A Cataldo, F Abbasi, T L McLaughlin, C Lamendola, and G M Reaven, “Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone,” Fertility and Sterility, vol. 76, no. 5, pp. 1057–1059, 2001.
View at: Publisher Site | Google Scholar
N A Cataldo, F Abbasi, T L McLaughlin et al., “Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome,” Human Reproduction, vol. 21, no. 1, pp. 109–120, 2006.
View at: Publisher Site | Google Scholar
V Sepilian and M Nagamani, “Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 60–65, 2005.
View at: Publisher Site | Google Scholar
S H Belli, M N Graffigna, A Oneto, P Otero, L Schurman, and O A Levalle, “Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 3, pp. 624–629, 2004.
View at: Publisher Site | Google Scholar
M FM Mitwally, N K Kuscu, and T M Yalcinkaya, “High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome,” Human Reproduction, vol. 14, no. 11, pp. 2700–2703, 1999.
View at: Publisher Site | Google Scholar
G Ghazeeri, W H Kutteh, M Bryer-Ash, D Haas, and R W Ke, “Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 79, no. 3, pp. 562–566, 2003.
View at: Publisher Site | Google Scholar
C Ortega-González, S Luna, L Hernández et al., “Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1360–1365, 2005.
View at: Publisher Site | Google Scholar
Y Barak, M C Nelson, E S Ong et al., “PPAR $γ$ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
View at: Publisher Site | Google Scholar
J Sevillano, I C López-Pérez, E Herrera, M Del Pilar Ramos, and C Bocos, “Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates,” Biochemical Journal, vol. 389, no. 3, pp. 913–918, 2005.
View at: Publisher Site | Google Scholar
F Yaris, E Yaris, M Kadioglu, C Ulku, M Kesim, and N I Kalyoncu, “Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman,” Reproductive Toxicology, vol. 18, no. 4, pp. 619–621, 2004.
View at: Publisher Site | Google Scholar
N I Kalyoncu, F Yaris, C Ulku et al., “A case of rosiglitazone exposure in the second trimester of pregnancy,” Reproductive Toxicology, vol. 19, no. 4, pp. 563–564, 2005.
View at: Publisher Site | Google Scholar
C J Glueck, H Phillips, D Cameron, L Sieve-Smith, and P Wang, “Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study,” Fertility and Sterility, vol. 75, no. 1, pp. 46–52, 2001.
View at: Publisher Site | Google Scholar
A H Balen, S-L Tan, J MacDougall, and H S Jacobs, “Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin,” Human Reproduction, vol. 8, no. 6, pp. 959–964, 1993.
View at: Google Scholar
L Harborne, R Fleming, H Lyall, J Norman, and N Sattar, “Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome,” Lancet, vol. 361, no. 9372, pp. 1894–1901, 2003.
View at: Publisher Site | Google Scholar
R V Mehta, K S Patel, M S Coffler et al., “Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 2136–2141, 2005.
View at: Publisher Site | Google Scholar
J A Downing and R J Scaramuzzi, “Nutrient effects on ovulation rate, ovarian function and the secretion of gonadotrophic and metabolic hormones in sheep,” Journal of Reproduction and Fertility. Supplement, vol. 43, pp. 209–227, 1991.
View at: Google Scholar
D I Lebovic, M Kir, and C L Casey, “Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis,” Fertility and Sterility, vol. 82, no. suppl 3, pp. 1008–1013, 2004.
View at: Publisher Site | Google Scholar
Y Cui, K Miyoshi, E Claudio et al., “Loss of the peroxisome proliferation-activated receptor gamma (PPAR $γ$ ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility,” Journal of Biological Chemistry, vol. 277, no. 20, pp. 17830–17835, 2002.
View at: Publisher Site | Google Scholar
D Duffy, G Montgomery, S Treloar et al., “IBD sharing around the PPARG locus is not increased in dizygotic twins or their mothers,” Nature Genetics, vol. 28, no. 4, p. 315, 2001.
View at: Publisher Site | Google Scholar
D Seto-Young, M Paliou, J Schlosser et al., “Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 11, pp. 6099–6105, 2005.
View at: Publisher Site | Google Scholar
Y-M Mu, T Yanase, Y Nishi et al., “Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 710–713, 2000.
View at: Publisher Site | Google Scholar
D S Willis, J White, S Brosens, and S Franks, “Effect of 15-deoxy-(12,14)-prostaglandin J2(PGJ2) a peroxisome proliferator activating receptor (PPAR) ligand on human ovarian steroidogenesis,” Endocrinology, no. suppl 1, p. 491, 1999, (abstract P3-247).
View at: Google Scholar
J D Veldhuis, G Zhang, and J C Garmey, “Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1129–1133, 2002.
View at: Publisher Site | Google Scholar
S Gasic, M Nagamani, A Green, and R J Urban, “Troglitazone is a competitive inhibitor of 3 $β$ -hydroxysteroid dehydrogenase enzyme in the ovary,” American Journal of Obstetrics and Gynecology, vol. 184, no. 4, pp. 575–579, 2001.
View at: Publisher Site | Google Scholar
M S Coffler, K Patel, M H Dahan, R Y Yoo, P J Malcom, and R J Chang, “Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 12, pp. 5624–5631, 2003.
View at: Publisher Site | Google Scholar
D Avtanski, J Kaplun, M Strizhevsky et al., “Interactions among PPAR-, insulin signaling pathways and aromatase in human ovarian cells,” in Proceedings of the 88th Annual Meeting of the Endocrine Society (ENDO '06), Boston, Mass, June 2006, (abstract P1-397).
View at: Google Scholar
A Dunaif and A Thomas, “Current concepts in the polycystic ovary syndrome,” Annual Review of Medicine, vol. 52, pp. 401–419, 2001.
View at: Publisher Site | Google Scholar
T Yamauchi, J Kamon, H Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor $γ$ (PPAR $γ$ ) deficiency and PPAR $γ$ agonist improve insulin resistance,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001.
View at: Publisher Site | Google Scholar
J Holte, T Bergh, C Berne, and H Lithell, “Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables,” Clinical Endocrinology, vol. 41, no. 4, pp. 463–471, 1994.
View at: Google Scholar
A A Parulkar, M L Pendergrass, R Granda-Ayala, T R Lee, and V A Fonseca, “Nonhypoglycemic effects of thiazolidinediones,” Annals of Internal Medicine, vol. 134, no. 1, pp. 61–71, 2001.
View at: Google Scholar
G W Bates and N S Whitworth, “Effect of body weight reduction on plasma androgens in obese, infertile women,” Fertility and Sterility, vol. 38, no. 4, pp. 406–409, 1982.
View at: Google Scholar
M-M Huber-Buchholz, D GP Carey, and R J Norman, “Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 4, pp. 1470–1474, 1999.
View at: Publisher Site | Google Scholar
T M Larsen, S Toubro, and A Astrup, “PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?,” International Journal of Obesity, vol. 27, no. 2, pp. 147–161, 2003.
View at: Publisher Site | Google Scholar
P Arner, “The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones,” Trends in Endocrinology and Metabolism, vol. 14, no. 3, pp. 137–145, 2003.
View at: Publisher Site | Google Scholar
P Björntorp, “The regulation of adipose tissue distribution in humans,” International Journal of Obesity, vol. 20, no. 4, pp. 291–302, 1996.
View at: Google Scholar
J Lord, R Thomas, B Fox, U Acharya, and T Wilkin, “The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 113, no. 10, pp. 1203–1209, 2006.
View at: Publisher Site | Google Scholar
E Budak, M Fernández Sánchez, J Bellver, A Cerveró, C Simón, and A Pellicer, “Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system,” Fertility and Sterility, vol. 85, no. 6, pp. 1563–1581, 2006.
View at: Publisher Site | Google Scholar
F Gonzalez, K Thusu, E Abdel-Rahman, A Prabhala, M Tomani, and P Dandona, “Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome,” Metabolism, vol. 48, no. 4, pp. 437–441, 1999.
View at: Publisher Site | Google Scholar
H F Escobar-Morreale, G Villuendas, J I Botella-Carretero et al., “Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study,” Human Reproduction, vol. 21, no. 9, pp. 2257–2265, 2006.
View at: Publisher Site | Google Scholar
A Okuno, H Tamemoto, K Tobe et al., “Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1354–1361, 1998.
View at: Google Scholar
C R Kahn, L Chen, and S E Cohen, “Unraveling the mechanism of action of thiazolidinediones,” Journal of Clinical Investigation, vol. 106, no. 11, pp. 1305–1307, 2000.
View at: Google Scholar
D Duran-Sandoval, A-C Thomas, B Bailleul, J-C Fruchart, and B Staels, “Pharmacology of PPAR $α$ , PPAR $γ$ and dual PPAR $α$ / $γ$ agonists in clinical development,” Medecine/Sciences, vol. 19, no. 8-9, pp. 819–825, 2003.
View at: Google Scholar
A Bodles, A Banga, N Rasouli, F Ono, P A Kern, and R J Owens, “Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes,” American Journal of Physiology - Endocrinology and Metabolism, vol. 291, no. 5, pp. E1100–E1105, 2006.
View at: Publisher Site | Google Scholar
V Sepilian and M Nagamani, “Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance,” Journal of the Society for Gynecologic Investigation, vol. 12, no. 2, pp. 129–134, 2005.
View at: Publisher Site | Google Scholar
F Jr Orio, S Palomba, T Cascella et al., “Adiponectin levels in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2619–2623, 2003.
View at: Publisher Site | Google Scholar
I Munir, H-W Yen, T Baruth et al., “Resistin stimulation of 17 $α$ -hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4852–4857, 2005.
View at: Publisher Site | Google Scholar
J M Lord, I HK Flight, and R J Norman, “Metformin in polycystic ovary syndrome: systematic review and meta-analysis,” British Medical Journal, vol. 327, no. 7421, pp. 951–953, 2003.
View at: Publisher Site | Google Scholar
R J Norman, “Editorial: metformin—comparison with other therapies in ovulation induction in polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4797–4800, 2004.
View at: Publisher Site | Google Scholar
N Musi, M F Hirshman, J Nygren et al., “Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes,” Diabetes, vol. 51, no. 7, pp. 2074–2081, 2002.
View at: Google Scholar
L Tosca, P Solnais, P Ferré, F Foufelle, and J Dupont, “Metformin-induced stimulation of adenosine $5^{'}$ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells,” Biology of Reproduction, vol. 75, no. 3, pp. 342–351, 2006.
View at: Publisher Site | Google Scholar
R Mansfield, R Galea, M Brincat, D Hole, and H Mason, “Metformin has direct effects on human ovarian steroidogenesis,” Fertility and Sterility, vol. 79, no. 4, pp. 956–962, 2003.
View at: Publisher Site | Google Scholar
A La Marca, T O Egbe, G Morgante, T Paglia, A Ciani, and V De Leo, “Metformin treatment reduces ovarian cytochrome P-450c17 $α$ response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome,” Human Reproduction, vol. 15, no. 1, pp. 21–23, 2000.
View at: Publisher Site | Google Scholar
M R Owen, E Doran, and A P Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000.
View at: Publisher Site | Google Scholar
L A Stadtmauer, S K Toma, R M Riehl, and L M Talbert, “Impact of metformin therapy on ovarian stimulation and outcome in ‘coasted’ patients with polycystic ovary syndrome undergoing in-vitro fertilization,” Reproductive Biomedicine Online, vol. 5, no. 2, pp. 112–116, 2002.
View at: Google Scholar
J-P Baillargeon, D J Jakubowicz, M J Iuorno, S Jakubowicz, and J E Nestler, “Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity,” Fertility and Sterility, vol. 82, no. 4, pp. 893–902, 2004.
View at: Publisher Site | Google Scholar
A A Rouzi and M SM Ardawi, “A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome,” Fertility and Sterility, vol. 85, no. 2, pp. 428–435, 2006.
View at: Publisher Site | Google Scholar
M Yilmaz, A Karakoç, F B Törüner et al., “The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome,” Gynecological Endocrinology, vol. 21, no. 3, pp. 154–160, 2005.
View at: Google Scholar
C J Glueck, A Moreira, N Goldenberg, L Sieve, and P Wang, “Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin,” Human Reproduction, vol. 18, no. 8, pp. 1618–1625, 2003.
View at: Publisher Site | Google Scholar
C Xu, L-L Wang, H-Y Liu et al., “A novel dual peroxisome proliferator-activated receptors $α$ and $γ$ agonist with beneficial effects on insulin resistance and lipid metabolism,” Biotechnology Letters, vol. 28, no. 12, pp. 863–868, 2006.
View at: Publisher Site | Google Scholar
C Fievet, J C Fruchart, and B Staels, “PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006.
View at: Google Scholar

Copyright

Copyright © 2006 Pascal Froment and Philippe Touraine. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies